Lori Lawley

Finansdirektör/CFO på LUMOS PHARMA, INC.

42 år

Health Technology

Commercial Services

Consumer Services

Profil

Lori Lawley is currently Chief Financial Officer & Secretary at Lumos Pharma, Inc. since 2020.
Former positions include Vice President-Finance & Controller at NewLink Genetics Corp.
from 2018 to 2020 and Senior Manager at Ernst & Young LLP from 2014 to 2015.
Education includes undergraduate and graduate degrees from McCombs School of Business.

Aktiva positioner av Lori Lawley

Företag	Position	Start
LUMOS PHARMA, INC.	Finansdirektör/CFO	2021-07-04

Alla aktiva positioner av Lori Lawley

Tidigare kända positioner av Lori Lawley

Företag	Position	Slut
LUMOS PHARMA, INC.	Comptroller/Controller/Revisor	2020-03-01
Ernst & Young LLP Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services	Företagsledare/Principal	2015-04-01

Se detaljerna i Lori Lawleys erfarenhet

Lori Lawleys utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Se detaljerna i Lori Lawleys erfarenhet

Relationer

Första gradens relationer

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Se det personliga nätverket

Kopplade företag

Privata företag	4
Ernst & Young LLP Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services	Commercial Services
NewLink Genetics Corp. NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops, and commercializes novel immunotherapeutic products for treatment of cancer	Health Technology
McCombs School of Business McCombs School of Business Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Lumos Pharma, Inc. Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases	Health Technology